Clinical Trials Logo

Clinical Trial Summary

Study participants with primary breast cancer will receive a standard chemotherapy with an anthracycline and a taxane as well as trastuzumab in case of HER2-positive tumors at doses and duration in concordance to current treatment guidelines. Patients will be receive and benefit in addition currently not in the neoadjuvant setting registered medication as lapatinib or bevacizumab of which significant increases of cure (pCR) rates have been reported in previous phase III studies. Patients randomized to carboplatin will receive in addition to the described backbone therapies a potentially active agent which suggested synergy of efficacy with chemotherapies as well as targeted agents. Patients might have the risk of an increase in toxicities due to the added agents and will have additional burden due to investigations required for study participation. However, due to the severity of the underlying disease and the high risk of relapse and death due to the stage of disease, this increase in toxicity and burden appears less relevant compared to the potential higher efficacy and finally cure rate by the incorporated treatments.


Clinical Trial Description

Anthracycline/taxane based combination chemotherapy of at least 18 weeks represents the standard of care in the neoadjuvant setting. In HER2-positive disease trastuzumab is given simultaneously to chemotherapy. Recent data from the Neo-Altto and Neosphere trials suggest that a dual blockage of the HER2 receptor with e.g. trastuzumab and lapatinib reach significantly higher pCR rates than trastuzumab alone and should therefore represent the treatment back-bone of new neoadjuvant trials. A preplanned subgroup analysis of the GeparQuinto study demonstrated that in TNBC the addition of bevacizumab resulted in a significant increase of pCR rates (HR 1.4).

Having a better cardiac tolerability profile compared to conventional anthracyclines, the non-pegylated liposomal encapsulated doxorubicin (NPLD) Myocet® might provide the possibility to combine taxane, anthracycline, platinum salt as well with targeted agents as double HER2 blockage or bevacizumab. ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01426880
Study type Interventional
Source German Breast Group
Contact
Status Completed
Phase Phase 2/Phase 3
Start date August 2011
Completion date August 2013

See also
  Status Clinical Trial Phase
Completed NCT00344071 - Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia N/A
Recruiting NCT05383196 - Onvansertib + Paclitaxel In TNBC Phase 1/Phase 2
Active, not recruiting NCT02221999 - Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients Phase 2/Phase 3
Completed NCT02324088 - Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer Phase 3
Completed NCT00003199 - Combination Chemotherapy and Peripheral Blood Stem Cell Transplant Followed By Aldesleukin and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer Phase 2
Terminated NCT00016276 - Combination Chemotherapy, Surgery, and Radiation Therapy With or Without Dexrazoxane and Trastuzumab in Treating Women With Stage III or Stage IV Breast Cancer Phase 3
Recruiting NCT01880385 - Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer Phase 1
Not yet recruiting NCT06131632 - Conserving Surgery in Inflammatory Breast Cancer After Neoadjuvant Chemotherapy N/A
Completed NCT00513695 - Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer Phase 2
Completed NCT00340158 - Establishing an Inflammatory Breast Cancer Registry N/A
Recruiting NCT04636710 - Refining Local-Regional Therapy for IBC N/A
Active, not recruiting NCT05415215 - A Study to Evaluate Patient Preference for Home Administration of Fixed-Dose Combination of Pertuzumab and Trastuzumab for Subcutaneous Administration in Participants With Early or Locally Advanced/Inflammatory HER2-Positive Breast Cancer Phase 3
Recruiting NCT04030507 - Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer N/A
Recruiting NCT03515798 - Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer Phase 2
Completed NCT01583426 - Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) Phase 3
Recruiting NCT02879513 - Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy Phase 3
Completed NCT02199418 - Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer Phase 2
Active, not recruiting NCT02623972 - A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer Phase 2
Recruiting NCT00891280 - Dose-escalation Study of Oral CX-4945 Phase 1
Completed NCT00049114 - Tipifarnib, Doxorubicin, and Cyclophosphamide in Treating Women With Locally Advanced Breast Cancer Phase 2